# PACIRA BIOSCIENCES, INC. (PCRX) FY2026 YTD Q2 P&L / Income Statement

- Company: PACIRA BIOSCIENCES, INC. (PCRX)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-04, accession number 0001628280-26-052635
- Page: https://plicit.ai/financials/pcrx/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/pcrx-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service (5 categories)

Income statement for 2026-01-01 through 2026-06-30. View: Product and service (5 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 369,775,000 US dollars
- **Cost of goods sold (exclusive of amortization of acquired intangible assets)**: 80,577,000 US dollars
- **Gross profit (calculated)**: 289,198,000 US dollars
- **Operating expenses (calculated)**: 278,029,000 US dollars
- **Income from operations**: 11,169,000 US dollars
- **Total other expense, net**: negative 3,616,000 US dollars
- **Income (loss) before income taxes**: 7,553,000 US dollars
- **Income tax benefit (expense)**: negative 16,000 US dollars
- **Net income (loss)**: 7,569,000 US dollars
- **EXPAREL**: 291,097,000 US dollars
- **ZILRETTA**: 59,415,000 US dollars
- **iovera°**: 12,982,000 US dollars
- **Bupivacaine liposome injectable suspension**: 4,375,000 US dollars
- **Royalty revenue**: 1,906,000 US dollars
- **Research and development**: 58,315,000 US dollars
- **Selling, general and administrative**: 185,753,000 US dollars
- **Amortization of acquired intangible assets**: 28,644,000 US dollars
- **Other operating expenses, net**: 5,317,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (2 categories)

- Page: https://plicit.ai/financials/pcrx/fy2026-ytd-q2-income-statement/revenue-by-product-and-service-2-categories
- Chart image: https://plicit.ai/charts/pcrx-fy2026-ytd-q2-revenue-by-product-and-service-2-categories-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 369,775,000 US dollars
- **Cost of goods sold (exclusive of amortization of acquired intangible assets)**: 80,577,000 US dollars
- **Gross profit (calculated)**: 289,198,000 US dollars
- **Operating expenses (calculated)**: 278,029,000 US dollars
- **Income from operations**: 11,169,000 US dollars
- **Total other expense, net**: negative 3,616,000 US dollars
- **Income (loss) before income taxes**: 7,553,000 US dollars
- **Income tax benefit (expense)**: negative 16,000 US dollars
- **Net income (loss)**: 7,569,000 US dollars
- **Net product sales**: 367,869,000 US dollars
- **Royalty revenue**: 1,906,000 US dollars
- **Research and development**: 58,315,000 US dollars
- **Selling, general and administrative**: 185,753,000 US dollars
- **Amortization of acquired intangible assets**: 28,644,000 US dollars
- **Other operating expenses, net**: 5,317,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.